{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T02:00:39Z","timestamp":1774663239499,"version":"3.50.1"},"reference-count":120,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","bmn.com","clinicalkey.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.tips.2025.02.004","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T15:24:22Z","timestamp":1742225062000},"page":"357-371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Emerging autism and Fragile X syndrome treatments"],"prefix":"10.1016","volume":"46","author":[{"given":"Michael","family":"Parkhill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalina","family":"Salmaso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amedeo","family":"D\u2019Angiulli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Argel","family":"Aguilar-Valles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.02.004_bb0005","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2022.23661","article-title":"Autism spectrum disorder: a review","volume":"329","author":"Hirota","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2025.02.004_bb0010","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1001\/jamapsychiatry.2019.1411","article-title":"Association of genetic and environmental factors with autism in a 5-country cohort","volume":"76","author":"Bai","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0015","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2019.00385","article-title":"Genetic causes and modifiers of autism spectrum disorder","volume":"13","author":"Rylaarsdam","year":"2019","journal-title":"Front. Cell. Neurosci."},{"key":"10.1016\/j.tips.2025.02.004_bb0020","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.21037\/tp.2019.09.09","article-title":"Autism spectrum disorder: definition, epidemiology, causes, and clinical evaluation","volume":"9","author":"Hodges","year":"2020","journal-title":"Transl. Pediatr."},{"key":"10.1016\/j.tips.2025.02.004_bb0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-024-03479-5","article-title":"Familial confounding in the associations between maternal health and autism","author":"Khachadourian","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0030","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fgene.2018.00406","article-title":"De novo mutations (DNMs) in autism spectrum disorder (ASD): pathway and network analysis","volume":"9","author":"Alonso-Gonzalez","year":"2018","journal-title":"Front. Genet."},{"key":"10.1016\/j.tips.2025.02.004_bb0035","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.neubiorev.2021.06.028","article-title":"Genetic architecture of autism spectrum disorder: Lessons from large-scale genomic studies","volume":"128","author":"Choi","year":"2021","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.tips.2025.02.004_bb0040","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s11689-021-09362-5","article-title":"Autism spectrum disorder in females with fragile X syndrome: a systematic review and meta-analysis of prevalence","volume":"13","author":"Marlborough","year":"2021","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1177\/0883073817712875","article-title":"Autism symptoms in fragile X syndrome","volume":"32","author":"Niu","year":"2017","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0050","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.3390\/ijms23041935","article-title":"Fragile X syndrome: from molecular aspect to clinical treatment","volume":"23","author":"Protic","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.02.004_bb0055","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.cell.2008.10.017","article-title":"The autistic neuron: troubled translation?","volume":"135","author":"Kelleher","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.02.004_bb0060","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1055\/s-0034-1386764","article-title":"Autism and fragile X syndrome","volume":"34","author":"Yu","year":"2014","journal-title":"Semin. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.psyneuen.2024.107067","article-title":"The effects of oxytocin administration on social and routinized behaviors in autism: a preregistered systematic review and meta-analysis","volume":"167","author":"Audunsdottir","year":"2024","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.tips.2025.02.004_bb0070","article-title":"The therapeutic effect of memantine through the stimulation of synapse formation and dendritic spine maturation in autism and fragile X syndrome","volume":"7","author":"Wei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2025.02.004_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/ajmg.a.32697","article-title":"Cholinergic dysfunction in fragile X syndrome and potential intervention: a preliminary 1H MRS study","volume":"149","author":"Kesler","year":"2009","journal-title":"Am. J. Med. Genet. A"},{"key":"10.1016\/j.tips.2025.02.004_bb0080","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/cge.13039","article-title":"Metformin as targeted treatment in fragile X syndrome","volume":"93","author":"Dy","year":"2018","journal-title":"Clin. Genet."},{"key":"10.1016\/j.tips.2025.02.004_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2021.110307","article-title":"The safety and efficacy of metformin in fragile X syndrome: an open-label study","volume":"110","author":"Proteau-Lemieux","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0090","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1177\/0269881119858304","article-title":"Brain circuitry, behavior, and cognition: a randomized placebo-controlled trial of donepezil in fragile X syndrome","volume":"33","author":"Bruno","year":"2019","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.tips.2025.02.004_bb0095","article-title":"Memantine for autism spectrum disorder","volume":"8","author":"Brignell","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.tips.2025.02.004_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s11689-016-9181-6","article-title":"Arbaclofen in fragile X syndrome: results of phase 3 trials","volume":"9","author":"Berry-Kravis","year":"2017","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0105","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/ana.26249","article-title":"Profile of autism spectrum disorder in tuberous sclerosis complex: results from a longitudinal, prospective, multi-site study","volume":"90","author":"Capal","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-021-09357-2","article-title":"mTOR inhibitor improves autistic-like behaviors related to Tsc2 haploinsufficiency but not following developmental status epilepticus","volume":"13","author":"Petrasek","year":"2021","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms2295","article-title":"Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex","volume":"3","author":"Sato","year":"2012","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.02.004_bb0120","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/acn3.494","article-title":"Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders","volume":"4","author":"Krueger","year":"2017","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0125","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-21327-9","article-title":"Multi-angle meta-analysis of the gut microbiome in autism spectrum disorder: a step toward understanding patient subgroups","volume":"12","author":"West","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.02.004_bb0130","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.3390\/ijms20092115","article-title":"The possible role of the microbiota-gut-brain-axis in autism spectrum disorder","volume":"20","author":"Srikantha","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.02.004_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.578386","article-title":"Anti-inflammatory and immunomodulatory effects of probiotics in gut inflammation: a door to the body","volume":"12","author":"Cristofori","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.02.004_bb0140","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3390\/nu11030521","article-title":"Autism spectrum disorders and the gut microbiota","volume":"11","author":"Fattorusso","year":"2019","journal-title":"Nutrients"},{"key":"10.1016\/j.tips.2025.02.004_bb0145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13229-016-0110-z","article-title":"Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders","volume":"7","author":"Fiorentino","year":"2016","journal-title":"Mol. Autism"},{"key":"10.1016\/j.tips.2025.02.004_bb0150","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/advances\/nmy063","article-title":"Mechanisms of action of probiotics","volume":"10","author":"Plaza-Diaz","year":"2019","journal-title":"Adv. Nutr."},{"key":"10.1016\/j.tips.2025.02.004_bb0155","doi-asserted-by":"crossref","first-page":"6729","DOI":"10.3390\/ijms22136729","article-title":"Probiotics, prebiotics and epithelial tight junctions: a promising approach to modulate intestinal barrier function","volume":"22","author":"Rose","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tips.2025.02.004_bb0160","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/ibd.20602","article-title":"Mechanisms of action of probiotics: recent advances","volume":"15","author":"Ng","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.tips.2025.02.004_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2023.1123462","article-title":"A review of probiotics in the treatment of autism spectrum disorders: perspectives from the gut\u2013brain axis","volume":"14","author":"Feng","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.tips.2025.02.004_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2022.113965","article-title":"Lactobacillus plantarum ST-III modulates abnormal behavior and gut microbiota in a mouse model of autism spectrum disorder","volume":"257","author":"Guo","year":"2022","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.tips.2025.02.004_bb0175","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1039\/D0FO02375B","article-title":"Daily intake of Lactobacillus alleviates autistic-like behaviors by ameliorating the 5-hydroxytryptamine metabolic disorder in VPA-treated rats during weaning and sexual maturation","volume":"12","author":"Kong","year":"2021","journal-title":"Food Funct."},{"key":"10.1016\/j.tips.2025.02.004_bb0180","doi-asserted-by":"crossref","first-page":"5399","DOI":"10.1038\/s41598-022-09350-2","article-title":"Novel probiotic treatment of autism spectrum disorder associated social behavioral symptoms in two rodent models","volume":"12","author":"Mint\u00e1l","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.02.004_bb0185","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/brainsci12060781","article-title":"Selective probiotic treatment positively modulates the microbiota\u2013gut\u2013brain axis in the BTBR mouse model of autism","volume":"12","author":"Pochakom","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.tips.2025.02.004_bb0190","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.bbi.2018.05.015","article-title":"Dysbiosis of microbiome and probiotic treatment in a genetic model of autism spectrum disorders","volume":"73","author":"Tabouy","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2025.02.004_bb0195","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/aur.2079","article-title":"Oral probiotic administration during pregnancy prevents autism-related behaviors in offspring induced by maternal immune activation via anti-inflammation in mice","volume":"12","author":"Wang","year":"2019","journal-title":"Autism Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4172\/2329-8901.1000102","article-title":"Improvements in gastrointestinal symptoms among children with autism spectrum disorder receiving the Delpro\u00ae probiotic and immunomodulator formulation","volume":"1","author":"Sichel","year":"2013","journal-title":"J. Probiotics Health"},{"key":"10.1016\/j.tips.2025.02.004_bb0205","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1080\/1028415X.2017.1347746","article-title":"The role of probiotics in children with autism spectrum disorder: a prospective, open-label study","volume":"21","author":"Shaaban","year":"2018","journal-title":"Nutr. Neurosci."},{"key":"10.1016\/j.tips.2025.02.004_bb0210","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.550593","article-title":"Effects of probiotic supplementation on gastrointestinal, sensory and core symptoms in autism spectrum disorders: a randomized controlled trial","volume":"11","author":"Santocchi","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-023-02307-7","article-title":"Fecal microbiota transplantation improves VPA-induced ASD mice by modulating the serotonergic and glutamatergic synapse signaling pathways","volume":"13","author":"Wang","year":"2023","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0220","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40168-016-0225-7","article-title":"Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study","volume":"5","author":"Kang","year":"2017","journal-title":"Microbiome"},{"key":"10.1016\/j.tips.2025.02.004_bb0225","doi-asserted-by":"crossref","first-page":"5821","DOI":"10.1038\/s41598-019-42183-0","article-title":"Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota","volume":"9","author":"Kang","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.02.004_bb0230","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.bbi.2011.08.007","article-title":"The role of immune dysfunction in the pathophysiology of autism","volume":"26","author":"Onore","year":"2012","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2025.02.004_bb0235","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jneuroim.2008.12.002","article-title":"Elevated immune response in the brain of autistic patients","volume":"207","author":"Li","year":"2009","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.tips.2025.02.004_bb0240","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.77","article-title":"Atopic diseases and inflammation of the brain in the pathogenesis of autism spectrum disorders","volume":"6","author":"Theoharides","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0245","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1080\/19390211.2021.2005733","article-title":"Palmitoylethanolamide: a potential alternative to cannabidiol","volume":"20","author":"Clayton","year":"2023","journal-title":"J. Diet. Suppl."},{"key":"10.1016\/j.tips.2025.02.004_bb0250","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/j.1365-2567.2005.02156.x","article-title":"The flavonoid luteolin prevents lipopolysaccharide-induced NF-\u03baB signalling and gene expression by blocking I\u03baB kinase activity in intestinal epithelial cells and bone-marrow derived dendritic cells","volume":"115","author":"Kim","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.tips.2025.02.004_bb0255","first-page":"57","article-title":"Luteolin protects rat PC 12 and C6 cells against MPP+ induced toxicity via an ERK dependent Keapl-Nrf2-ARE pathway","volume":"72","author":"Wruck","year":"2007","journal-title":"J. Neural Transm. Suppl."},{"key":"10.1016\/j.tips.2025.02.004_bb0260","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/biof.1687","article-title":"Neuroprotective effects of flavone luteolin in neuroinflammation and neurotrauma","volume":"47","author":"Kempuraj","year":"2021","journal-title":"BioFactors"},{"key":"10.1016\/j.tips.2025.02.004_bb0265","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/cns.12648","article-title":"Beneficial effects of co-ultramicronized palmitoylethanolamide\/luteolin in a mouse model of autism and in a case report of autism","volume":"23","author":"Bertolino","year":"2017","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.tips.2025.02.004_bb0270","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bbi.2018.09.003","article-title":"Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf\/J mice: contribution of central and peripheral mechanisms","volume":"74","author":"Cristiano","year":"2018","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.tips.2025.02.004_bb0275","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1007\/s12028-022-01511-5","article-title":"Minocycline attenuates microglia\/macrophage phagocytic activity and inhibits SAH-induced neuronal cell death and inflammation","volume":"37","author":"Blecharz-Lang","year":"2022","journal-title":"Neurocrit. Care."},{"key":"10.1016\/j.tips.2025.02.004_bb0280","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/bph.12139","article-title":"Minocycline: far beyond an antibiotic","volume":"169","author":"Garrido-Mesa","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.tips.2025.02.004_bb0285","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.95.26.15769","article-title":"Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia","volume":"95","author":"Yrj\u00e4nheikki","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.02.004_bb0290","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1111\/ene.13403","article-title":"Minocycline and matrix metalloproteinase inhibition in acute intracerebral hemorrhage: a pilot study","volume":"24","author":"Chang","year":"2017","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0295","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1016\/j.bbagen.2014.03.007","article-title":"Matrix metalloproteinases in inflammation","volume":"1840","author":"Nissinen","year":"2014","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.tips.2025.02.004_bb0300","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1001\/archneurol.2010.191","article-title":"Prospects for minocycline neuroprotection","volume":"67","author":"Plane","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0305","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2015.10.052","article-title":"Minocycline ameliorates prenatal valproic acid induced autistic behaviour, biochemistry and blood brain barrier impairments in rats","volume":"1630","author":"Kumar","year":"2016","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0310","doi-asserted-by":"crossref","DOI":"10.1007\/s10803-023-06132-1","article-title":"Brief report: a double-blind, placebo-controlled, crossover, proof-of-concept study of minocycline in autism spectrum disorder","author":"Erickson","year":"2023","journal-title":"J. Autism Dev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0315","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1136\/jmg.2008.061796","article-title":"Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model","volume":"46","author":"Bilousova","year":"2009","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.tips.2025.02.004_bb0320","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.brainres.2011.12.041","article-title":"Minocycline treatment reverses ultrasonic vocalization production deficit in a mouse model of Fragile X syndrome","volume":"1439","author":"Rotschafer","year":"2012","journal-title":"Brain Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0325","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/DBP.0b013e318287cd17","article-title":"A randomized double-blind, placebo-controlled trial of minocycline in children and adolescents with fragile x syndrome","volume":"34","author":"Leigh","year":"2013","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.tips.2025.02.004_bb0330","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1352\/1944-7558-115.5.433","article-title":"Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures","volume":"115","author":"Utari","year":"2010","journal-title":"Am. J. Intellect. Dev. Disabil."},{"key":"10.1016\/j.tips.2025.02.004_bb0335","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1471-2377-10-91","article-title":"Open-label add-on treatment trial of minocycline in fragile X syndrome","volume":"10","author":"Paribello","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.762967","article-title":"Combining lovastatin and minocycline for the treatment of Fragile X syndrome: results from the LovaMiX clinical trial","volume":"12","author":"Champigny","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0345","series-title":"StatPearls","article-title":"Intravenous immunoglobulin (IVIG)","author":"Arumugham","year":"2023"},{"key":"10.1016\/j.tips.2025.02.004_bb0350","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1093\/intimm\/dxx039","article-title":"IVIG-mediated effector functions in autoimmune and inflammatory diseases","volume":"29","author":"Galeotti","year":"2017","journal-title":"Int. Immunol."},{"key":"10.1016\/j.tips.2025.02.004_bb0355","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/aur.1906","article-title":"A pilot study of high-dose intravenous immunoglobulin 5% for autism: impact on autism spectrum and markers of neuroinflammation","volume":"11","author":"Melamed","year":"2018","journal-title":"Autism Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0360","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000931","article-title":"The cyclic AMP cascade is altered in the Fragile X nervous system","volume":"2","author":"Kelley","year":"2007","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2025.02.004_bb0365","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00161","article-title":"Global and local missions of cAMP signaling in neural plasticity, learning, and memory","volume":"6","author":"Lee","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.tips.2025.02.004_bb0370","doi-asserted-by":"crossref","DOI":"10.1016\/j.conb.2024.102966","article-title":"The promise of cyclic AMP modulation to restore cognitive function in neurodevelopmental disorders","volume":"90","author":"Bhattacharya","year":"2025","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.tips.2025.02.004_bb0375","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15028-x","article-title":"Multiple behavior phenotypes of the Fragile-X syndrome mouse model respond to chronic inhibition of phosphodiesterase-4D (PDE4D)","volume":"7","author":"Gurney","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tips.2025.02.004_bb0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2021.105485","article-title":"Effects of chronic inhibition of phosphodiesterase-4D on behavior and regional rates of cerebral protein synthesis in a mouse model of fragile X syndrome","volume":"159","author":"Rosenheck","year":"2021","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.tips.2025.02.004_bb0385","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41591-021-01321-w","article-title":"Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial","volume":"27","author":"Berry-Kravis","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0390","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1136\/bmj.1.5794.211","article-title":"Bumetanide: potent new \u201cloop\u201d diuretic","volume":"1","author":"Asbury","year":"1972","journal-title":"Br. Med. J."},{"key":"10.1016\/j.tips.2025.02.004_bb0395","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.neuron.2009.03.003","article-title":"Cation-chloride cotransporters and neuronal function","volume":"61","author":"Blaesse","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2025.02.004_bb0400","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1523\/JNEUROSCI.4447-13.2014","article-title":"The developmental switch in GABA polarity is delayed in fragile X mice","volume":"34","author":"He","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.tips.2025.02.004_bb0405","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.tins.2017.07.001","article-title":"NKCC1 chloride importer antagonists attenuate many neurological and psychiatric disorders","volume":"40","author":"Ben-Ari","year":"2017","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.tips.2025.02.004_bb0410","first-page":"1","article-title":"Nanoformulated bumetanide ameliorates social deficiency in BTBR mice model of autism spectrum disorder","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tips.2025.02.004_bb0415","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1126\/science.1247190","article-title":"Oxytocin-mediated GABA inhibition during delivery attenuates autism pathogenesis in rodent offspring","volume":"343","author":"Tyzio","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.tips.2025.02.004_bb0420","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41380-018-0048-y","article-title":"Critical period inhibition of NKCC1 rectifies synapse plasticity in the somatosensory cortex and restores adult tactile response maps in fragile X mice","volume":"24","author":"He","year":"2019","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0425","article-title":"Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders","volume":"7","author":"Lemonnier","year":"2017","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0430","article-title":"Symptom improvement in children with autism spectrum disorder following bumetanide administration is associated with decreased GABA\/glutamate ratios","volume":"10","author":"Zhang","year":"2020","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0435","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.scib.2021.01.008","article-title":"Improved symptoms following bumetanide treatment in children aged 3\u22126 years with autism spectrum disorder: a randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dai","year":"2021","journal-title":"Sci. Bull. (Beijing)"},{"key":"10.1016\/j.tips.2025.02.004_bb0440","doi-asserted-by":"crossref","first-page":"536","DOI":"10.2174\/1871527322666230404114911","article-title":"Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder","volume":"23","author":"Shaker","year":"2023","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.tips.2025.02.004_bb0445","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/aur.3005","article-title":"Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies","volume":"16","author":"Fuentes","year":"2023","journal-title":"Autism Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0450","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1111\/apa.12235","article-title":"Treating Fragile X syndrome with the diuretic bumetanide: a case report","volume":"102","author":"Lemonnier","year":"2013","journal-title":"Acta Paediatr. Int. J. Paediatr."},{"key":"10.1016\/j.tips.2025.02.004_bb0455","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13229-019-0256-6","article-title":"Lower circulating endocannabinoid levels in children with autism spectrum disorder","volume":"10","author":"Aran","year":"2019","journal-title":"Mol. Autism"},{"key":"10.1016\/j.tips.2025.02.004_bb0460","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13229-018-0203-y","article-title":"Plasma anandamide concentrations are lower in children with autism spectrum disorder","volume":"9","author":"Karhson","year":"2018","journal-title":"Mol. Autism"},{"key":"10.1016\/j.tips.2025.02.004_bb0465","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.tips.2025.02.004_bb0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2025.111588","article-title":"Pharmacological characterization of cannabidiol as a negative allosteric modulator of the 5-HT2A receptor","volume":"127","author":"Billard","year":"2025","journal-title":"Cell. Signal."},{"key":"10.1016\/j.tips.2025.02.004_bb0475","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.15","article-title":"Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia","volume":"2","author":"Leweke","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0480","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1248\/bpb.19.1109","article-title":"Inhibition of anandamide amidase activity in mouse brain microsomes by cannabinoids","volume":"19","author":"Watanabe","year":"1996","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.tips.2025.02.004_bb0485","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"key":"10.1016\/j.tips.2025.02.004_bb0490","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.3389\/fneur.2019.01145","article-title":"Effects of CBD-enriched Cannabis sativa extract on autism spectrum disorder symptoms: an observational study of 18 participants undergoing compassionate use","volume":"10","author":"Fleury-Teixeira","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.tips.2025.02.004_bb0495","article-title":"Evaluation of the efficacy and safety of cannabidiol-rich cannabis extract in children with autism spectrum disorder: randomized, double-blind, and placebo-controlled clinical trial","volume":"46","author":"da Silva","year":"2024","journal-title":"Trends Psychiatry Psychother."},{"key":"10.1016\/j.tips.2025.02.004_bb0500","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2023.1210155","article-title":"Individually tailored dosage regimen of full-spectrum Cannabis extracts for autistic core and comorbid symptoms: a real-life report of multi-symptomatic benefits","volume":"14","author":"Montagner","year":"2023","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.tips.2025.02.004_bb0505","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.pbb.2019.05.002","article-title":"Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism","volume":"181","author":"Zieba","year":"2019","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.tips.2025.02.004_bb0510","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.3390\/cells12151927","article-title":"Early administration of the phytocannabinoid cannabidivarin prevents the neurobehavioral abnormalities associated with the Fmr1-KO mouse model of Fragile X syndrome","volume":"12","author":"Premoli","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tips.2025.02.004_bb0515","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/can.2018.0053","article-title":"Treatment of Fragile X syndrome with cannabidiol: a case series study and brief review of the literature","volume":"4","author":"Tartaglia","year":"2019","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0520","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s11689-019-9277-x","article-title":"A phase 1\/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome","volume":"11","author":"Heussler","year":"2019","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0525","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s11689-022-09466-6","article-title":"A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)","volume":"14","author":"Berry-Kravis","year":"2022","journal-title":"J. Neurodev. Disord."},{"key":"10.1016\/j.tips.2025.02.004_bb0530","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00213-013-3289-0","article-title":"The challenges of clinical trials in fragile X syndrome","volume":"231","author":"Jacquemont","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2025.02.004_bb0535","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euroneuro.2021.05.010","article-title":"Drug development for autism spectrum disorder (ASD): progress, challenges, and future directions","volume":"48","author":"McCracken","year":"2021","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.tips.2025.02.004_bb0540","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1523\/ENEURO.0143-15.2016","article-title":"Normal performance of Fmr1 mice on a touchscreen delayed nonmatching to position working memory task","volume":"3","author":"Leach","year":"2016","journal-title":"eNeuro"},{"key":"10.1016\/j.tips.2025.02.004_bb0545","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/ng.3039","article-title":"Most genetic risk for autism resides with common variation","volume":"46","author":"Gaugler","year":"2014","journal-title":"Nat. Genet."},{"key":"10.1016\/j.tips.2025.02.004_bb0550","doi-asserted-by":"crossref","first-page":"260","DOI":"10.3390\/biom13020260","article-title":"Modeling autism spectrum disorders with induced pluripotent stem cell-derived brain organoids","volume":"13","author":"Santos","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.tips.2025.02.004_bb0555","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.neuron.2021.06.025","article-title":"The promise of precision medicine in autism","volume":"109","author":"Kostic","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.tips.2025.02.004_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103486","article-title":"Translating precision medicine for autism spectrum disorder: a pressing need","volume":"28","author":"P\u00e9rez-Cano","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2025.02.004_bb0565","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aab4109","article-title":"Mavoglurant in fragile X syndrome: results of two randomized, double-blind, placebo-controlled trials","volume":"8","author":"Berry-Kravis","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0570","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3001708","article-title":"Epigenetic modification of the FMR1 gene in fragile X syndrome is associated with differential response to the mGluR5 antagonist AFQ056","volume":"3","author":"Jacquemont","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0575","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1044\/persp2.SIG1.56","article-title":"A strengths-based approach to autism: neurodiversity and partnering with the autism community","volume":"2","author":"Donaldson","year":"2017","journal-title":"Perspect. ASHA Spec. Interest Groups"},{"key":"10.1016\/j.tips.2025.02.004_bb0580","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004218","article-title":"Reversal of disease-related pathologies in the fragile X mouse model by selective activation of GABAB receptors with arbaclofen","volume":"4","author":"Henderson","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0585","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3004214","article-title":"Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial","volume":"4","author":"Berry-Kravis","year":"2012","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.tips.2025.02.004_bb0590","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.bbr.2012.10.059","article-title":"Chronic administration of AFQ056\/mavoglurant restores social behaviour in Fmr1 knockout mice","volume":"239","author":"Gantois","year":"2013","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.tips.2025.02.004_bb0595","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1007\/s00213-012-2947-y","article-title":"Rescue of dendritic spine phenotype in Fmr1 KO mice with the mGluR5 antagonist AFQ056\/mavoglurant","volume":"231","author":"Pop","year":"2014","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.tips.2025.02.004_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11689-015-9134-5","article-title":"Mavoglurant in adolescents with fragile X syndrome: analysis of clinical global impression-improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study","volume":"8","author":"Bailey","year":"2015","journal-title":"J. Neurodev. Disord."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000240?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725000240?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T04:56:43Z","timestamp":1744088203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725000240"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":120,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0165614725000240"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.02.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Emerging autism and Fragile X syndrome treatments","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}